zika
viru
zikv
mosquitoborn
flaviviru
first
identifi
monkey
zika
forest
near
lake
victoria
uganda
sporad
outbreak
zikv
sinc
report
africa
histor
peopl
infect
zika
viru
mild
symptom
includ
fever
rash
muscl
pain
red
eye
headach
howev
zikv
pandem
began
south
america
central
america
caribbean
usa
suddenli
becom
global
public
health
importantli
zikv
recent
outbreak
caus
congenit
zika
syndrom
includ
microcephali
syndrom
sever
neurolog
zikv
primarili
transmit
bite
infect
aed
speci
mosquito
although
transmiss
mode
sexual
blood
transfus
maternalfet
also
current
fdaapprov
vaccin
antivir
drug
zikv
zikv
member
viru
famili
flavivirida
also
includ
global
preval
human
pathogen
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
japanes
enceph
viru
jev
zikv
genom
encod
singl
polyprotein
cleav
posttransl
three
structur
protein
capsid
premembran
envelop
seven
nonstructur
protein
e
protein
type
ii
fusion
protein
mediat
cellular
attach
membran
fusion
target
neutral
antibodi
ab
flaviviru
prm
protein
typic
associ
e
form
heterodim
import
proper
fold
coexpress
prm
e
sever
flavivirus
includ
zikv
result
secret
viruslik
particl
vlp
term
recombin
subvir
prm
protein
integr
part
virion
subvir
particl
undergo
cleavag
event
viru
therefor
prm
e
protein
primari
target
ration
design
subunit
recombin
flaviviru
vaccin
howev
protein
sever
flavivirus
shown
confer
protect
flaviviru
infect
anim
model
absenc
detect
neutral
whether
immun
zikv
protein
similar
protect
capabl
current
unknown
recent
sever
zikv
vaccin
candid
report
includ
nucleic
acid
dna
mrna
inactiv
viru
subunit
vlp
vector
vaccin
includ
adenoviru
vaccinia
viru
live
attenu
vaccin
candid
trigger
variou
degre
humor
cellular
immun
protect
rodent
andor
nonhuman
primat
model
among
candid
dna
vaccin
subunit
vaccin
inactiv
vaccin
initi
clinic
trial
current
zikv
subunit
dna
mrna
vaccin
target
e
prme
antigen
although
vaccin
candid
promis
explor
new
highli
efficaci
zikv
vaccin
need
vesicular
stomat
viru
vsv
prototyp
nonseg
negativesens
nn
rna
viru
belong
rhabdovirida
famili
vsv
natur
pathogen
livestock
cattl
swine
preexist
immun
vsv
human
vsv
excel
platform
vaccin
develop
vsv
accommod
multipl
foreign
gene
thu
develop
multival
antigen
highli
express
cell
cultur
anim
vsv
enabl
gener
strong
system
immun
respons
sudden
outbreak
ebola
viru
africa
vsvbase
ebola
viru
vaccin
test
human
clinic
gener
vsv
safe
human
although
high
dose
vsv
caus
side
effect
peopl
includ
joint
muscl
importantli
vsvbase
ebola
viru
vaccin
shown
highli
efficaci
protect
ebola
viru
infect
prepar
manuscript
betancourt
et
al
report
matern
antibodi
deriv
femal
mice
inocul
vsv
express
prme
protect
offspr
lethal
zikv
howev
whether
immun
anim
protect
zikv
infect
known
develop
methyltransferas
mtase
defect
rvsv
mtdvsv
base
zikv
vaccin
platform
recov
panel
rvsv
express
zikv
prme
e
e
truncat
mutant
mtdvsvbase
zikv
vaccin
candid
highli
attenu
remain
effect
trigger
zikvspecif
antibodi
cell
immun
mice
provid
complet
protect
zikv
challeng
immunocompet
balbc
type
interferon
receptordefici
mice
addit
found
protein
play
regulatori
role
zikvspecif
cell
respons
alon
confer
partial
protect
zikv
infect
collect
mtdvsvbase
vaccin
promis
vaccin
candid
zikv
determin
feasibl
use
vsv
vaccin
vector
deliv
zikv
protein
construct
thirteen
recombin
virus
use
wildtyp
vsv
genom
backbon
supplementari
fig
construct
allow
us
compar
immunogen
variou
combin
zikv
wildtyp
mutant
protein
includ
e
protein
sinc
known
flavivirus
main
target
neutral
antibodi
ab
zikv
e
protein
compos
ntermin
ectodomain
consist
three
domain
ii
iii
stem
ctermin
transmembran
tm
domain
supplementari
fig
major
neutral
epitop
locat
ectodomain
e
protein
first
construct
rvsve
would
express
fulllength
e
protein
includ
stemtm
domain
amino
acid
supplementari
fig
sinc
exact
boundari
ectodomain
stemtm
domain
unclear
construct
three
e
truncat
mutant
lack
predict
stemtm
domain
three
recombin
virus
express
ntermin
amino
acid
e
protein
respect
supplementari
fig
next
rvsv
express
e
e
delet
anchor
c
signal
peptid
gener
supplementari
fig
recombin
virus
name
rvsvae
also
construct
four
recombin
virus
would
coexpress
anchor
cprm
e
e
delet
polyprotein
supplementari
fig
addit
sinc
protein
flavivirus
shown
play
role
construct
express
prm
e
polyprotein
supplementari
fig
plaqu
form
rvsv
mm
mean
standard
deviat
diamet
plaqu
form
rvsv
express
zikv
antigen
rang
mm
diamet
supplementari
fig
suggest
express
zikv
protein
reduc
replic
spread
rvsv
next
compar
replic
kinet
rvsv
rvsve
rvsvprme
cell
cultur
found
signific
delay
replic
kinet
compar
parent
rvsv
p
student
ttest
supplementari
fig
next
assess
express
level
vsv
vector
e
protein
truncat
kda
fulllength
e
protein
detect
cell
infect
rvsvprme
rvsve
fig
b
protein
detect
infect
cell
fig
expect
smaller
e
protein
detect
cell
express
truncat
e
protein
consist
shorter
ctermin
domain
fig
quantit
analysi
three
independ
experi
show
rvsv
coexpress
prm
e
e
truncat
approxim
five
time
greater
e
protein
express
compar
rvsv
express
e
e
truncat
without
prm
western
blot
cell
cultur
supernat
show
rvsv
coexpress
prm
ee
truncat
releas
enough
ee
truncat
protein
supernat
easili
detect
without
need
concentr
supplementari
fig
b
express
prm
follow
truncat
e
like
result
secret
solubl
e
protein
also
secret
cell
cultur
medium
supplementari
fig
howev
ee
truncat
detect
cell
medium
rvsv
express
ee
truncat
alon
supplementari
fig
b
next
compar
express
level
ee
truncat
without
anchor
c
signal
peptid
vsv
vector
shown
fig
rvsv
construct
anchor
c
abund
express
ee
truncat
compar
rvsv
construct
without
anchor
c
e
truncat
also
detect
supernat
rvsv
construct
anchor
c
supplementari
fig
howev
fulllength
e
protein
still
detect
rvsvae
even
though
anchor
fuse
e
supplementari
fig
thu
coexpress
anchor
c
prm
ee
truncat
significantli
increas
e
express
andor
stabil
result
also
indic
prm
e
protein
proteolyt
cleav
polyprotein
secret
cell
cultur
supernat
also
determin
kinet
e
protein
express
fig
e
protein
detect
rvsvprme
h
postinfect
reach
highest
express
level
h
postinfect
declin
h
primarili
cell
lyse
time
point
indic
reduct
recombin
signific
delay
e
protein
express
e
protein
detect
h
reach
highest
level
h
postinfect
without
cell
death
indic
continu
high
level
e
protein
detect
cell
infect
rvsve
even
time
cell
lyse
express
e
protein
rvsvprme
rvsve
virusinfect
cell
confirm
methioninecystein
metabol
label
supplementari
fig
cell
infect
rvsve
rvsvprme
cell
cultur
medium
harvest
h
postinfect
two
type
particl
vsv
yellow
arrow
zikv
vlp
white
arrow
fig
supplementari
fig
detect
negativestain
electron
microscopi
separ
cscl
isopycn
gradient
centrifug
larg
number
low
densiti
zikv
vlp
obtain
rvsvprme
infect
cell
fig
supplementari
fig
c
zikv
vlp
express
vsv
diamet
nm
rel
smaller
nativ
zikv
virion
nm
fig
supplementari
fig
f
vlp
detect
cell
cultur
medium
cell
infect
rvsve
fig
supplementari
fig
therefor
result
confirm
express
prme
e
alon
vsv
vector
result
assembl
vlp
next
test
immunogen
nine
recombin
virus
mice
balbc
mice
inocul
intranas
singl
dose
pfu
recombin
viru
dna
vaccin
use
control
briefli
mice
intramuscularli
inject
pciprm
boost
dose
pciprm
two
week
later
mice
infect
rvsv
exhibit
sever
clinic
sign
includ
ataxia
hyperexcit
paralysi
day
postinocul
two
five
mice
dead
remain
three
mice
dead
day
postinocul
howev
rvsv
express
zikv
antigen
show
variou
degre
attenu
mice
inocul
recombin
virus
mild
clinic
sign
ruffl
coat
experienc
bodi
weight
loss
week
start
gain
weight
day
supplementari
fig
overal
rvsv
coexpress
prm
ee
truncat
mutant
attenu
mice
rvsv
express
ee
truncat
alon
exampl
rvsvprme
significantli
less
bodi
weight
loss
compar
rvsve
p
ttest
p
ttest
respect
day
postinocul
recombin
attenu
viru
supplementari
fig
mice
inocul
viru
experienc
littl
weight
loss
display
clinic
sign
experi
demonstr
rvsv
express
zikv
antigen
particularli
significantli
attenu
mice
compar
parent
rvsv
dynam
zikv
especif
ab
product
follow
vaccin
determin
elisa
summar
fig
week
postinocul
mice
inocul
rvsv
coexpress
prmee
truncat
mutant
high
level
serum
igg
zikv
e
protein
week
postinocul
mice
group
develop
igg
ab
ab
titer
increas
remain
high
level
week
contrast
none
mice
vaccin
rvsv
express
ee
truncat
mutant
without
prm
detect
zikvspecif
antibodi
week
true
week
ab
observ
group
increas
week
howev
ab
titer
group
significantli
lower
virus
coexpress
prmee
truncat
mutant
p
ttest
ab
detect
dna
vaccin
group
week
despit
fact
mice
given
two
dose
week
ab
detect
dna
vaccin
group
week
postimmun
also
lower
induc
rvsvprmee
truncat
result
demonstr
singledos
inocul
mice
rvsv
coexpress
prmee
truncat
trigger
high
level
serum
antibodi
respons
earli
week
postinocul
enhanc
safeti
vsv
vector
attenu
specif
mutat
inhibit
mrna
cap
methyltransferas
mtase
activ
previous
show
singl
point
mutat
sadenosyl
methionin
sam
bind
site
mtase
region
larg
l
polymeras
protein
result
recombin
viru
defect
mrna
cap
methyl
ribos
compar
rvsv
recombin
viru
highli
attenu
cell
cultur
well
mutat
introduc
vsv
backbon
gener
respect
supplementari
fig
plaqu
diamet
mm
respect
significantli
smaller
recombin
virus
deriv
wildtyp
vsv
backbon
compar
supplementari
fig
fig
singlestep
replic
curv
show
replic
kinet
similar
wherea
signific
delay
p
time
point
h
respect
ttest
fig
h
postinfect
express
e
rank
fig
e
protein
express
detect
protein
express
detect
fig
kinet
experi
e
protein
express
maxim
h
respect
delay
cell
fig
similarli
e
protein
secret
cell
cultur
medium
virusinfect
cell
fig
e
supplementari
fig
compar
parent
rvsv
vector
e
protein
express
delay
vector
fig
compar
upper
lower
panel
suggest
vector
attenu
result
demonstr
zikv
e
protein
highli
express
mtasedefect
rvsv
next
test
mtasedefect
vsv
mtdvsv
base
vaccin
balbc
mice
intranas
wildtyp
rvsv
kill
mice
within
day
fig
mice
inocul
show
weight
loss
day
postinfect
recov
day
fig
mice
inocul
exhibit
bodi
weight
loss
significantli
differ
dmem
control
p
ttest
fig
vsvassoci
clinic
symptom
indic
high
degre
attenu
high
level
zikv
especif
antibodi
detect
elisa
mice
week
postimmun
respect
fig
signific
differ
elisa
fig
neutral
antibodi
titer
fig
week
two
group
p
zikv
specif
antibodi
detect
dmem
group
compar
wildtyp
rvsv
backbon
mtdvsvbase
virus
delay
antibodi
respons
compar
fig
fig
reflect
signific
attenu
recombin
virus
addit
mice
group
develop
antibodi
detect
elisa
week
fig
result
demonstr
mtdvsvbase
zikv
vaccin
candid
highli
attenu
immunogen
mice
coexpress
regul
zikvspecif
cell
respons
induct
antigenspecif
ab
cytotox
cell
respons
capabl
provid
protect
immun
requir
helper
cell
cell
found
spleen
cell
mice
intranas
immun
restimul
vitro
zikv
e
protein
increas
number
helper
cell
fig
find
indic
immun
induc
zikv
especif
cell
capabl
prolifer
reexposur
e
antigen
cell
produc
import
cytokin
ie
product
complement
fix
ab
cytotox
cell
togeth
crucial
protect
intracellular
pathogen
virus
flow
cytometri
analysi
cell
produc
cytokin
reveal
cell
isol
mice
immun
express
zikv
antigenspecif
produc
helper
cell
fig
interestingli
produc
helper
cell
detect
spleen
mice
immun
result
indic
coexpress
enhanc
inhibit
product
helper
cell
cell
produc
array
cytokin
support
product
ab
like
protect
extracellular
pathogen
virus
interleukin
signatur
product
follicular
helper
cell
tfh
product
cell
facilit
antibodi
product
affin
matur
induc
similar
level
cytokin
p
ttest
spleen
cell
vitro
restimul
zikv
e
protein
fig
howev
induc
significantli
higher
two
cytokin
p
ttest
interestingli
also
induc
significantli
higher
respons
p
ttest
fig
addit
zikv
especif
tfh
cell
produc
similar
level
inocul
mice
p
ttest
fig
result
demonstr
mtdvsvbase
vaccin
trigger
zikvspecif
cell
respons
coexpress
enhanc
respons
addit
fact
coexpress
enhanc
suggest
modul
respons
fig
collect
result
suggest
presenc
lead
balanc
respons
includ
cell
next
determin
protect
effect
mtdvsvbase
zikv
vaccin
femal
male
balbc
mice
mice
vaccin
intranas
singl
dose
pfu
recombin
viru
challeng
intraven
pfu
zikv
cambodian
strain
week
postimmun
dna
vaccin
pciprm
use
control
given
intramuscularli
twice
week
similar
previou
observ
shown
fig
attenu
viru
experienc
weight
loss
supplementari
fig
recombin
virus
show
weight
loss
earli
time
point
weight
recov
day
supplementari
fig
previous
shown
administr
antibodi
render
balbc
mice
suscept
infect
mouseadapt
african
zikv
strain
dakar
similarli
passiv
transfer
mg
block
antibodi
mous
h
prior
intraven
challeng
zikv
cambodian
strain
zikv
challeng
mice
monitor
week
unexpectedli
signific
weight
loss
clinic
symptom
observ
group
includ
unvaccin
challeng
control
supplementari
fig
dynam
viremia
monitor
everi
day
day
zikv
challeng
except
pciprm
group
monitor
day
detect
realtim
rtpcr
unvaccin
challeng
control
peak
viremia
observ
day
declin
day
clear
day
fig
consist
previou
observ
zikv
caus
transient
viremia
balbc
similarli
mice
group
develop
viremia
shed
averag
log
zikv
pfu
equival
rnaml
blood
sampl
collect
day
postchalleng
fig
contrast
viremia
mice
vaccin
pciprm
group
detect
limit
day
mice
near
detect
limit
level
viremia
respect
mice
pciprm
group
high
level
viremia
fig
supplementari
fig
addit
viremia
detect
limit
day
group
fig
collect
data
show
singl
dose
vaccin
mtdvsvbase
vaccin
provid
protect
zikvinduc
viremia
balbc
mice
determin
whether
vsv
persist
vaccin
mice
brain
tissu
collect
termin
studi
detect
vsv
infecti
vsv
detect
plaqu
assay
brain
tissu
group
howev
log
vsv
rna
detect
brain
group
fig
contrast
nearli
vsv
rna
detect
group
fig
therefor
attenu
virus
next
repeat
anim
experi
includ
vaccin
recombin
bodi
weight
loss
wherea
approxim
bodi
weight
loss
day
supplementari
fig
high
especif
antibodi
observ
anim
vaccin
day
increas
day
postvaccin
fig
anim
vaccin
develop
especif
antibodi
day
anim
develop
especif
antibodi
day
fig
antibodi
detect
group
fig
upon
zikv
challeng
mice
exhibit
bodi
weight
loss
supplementari
fig
mice
vaccin
protect
viremia
day
fig
fig
postchalleng
wherea
mice
receiv
shed
high
titer
zikv
rna
blood
level
similar
salin
control
group
final
assess
protect
effect
mtdvsvbase
zikv
vaccin
mice
lack
typei
interferon
receptor
ifnar
mice
shown
highli
permiss
vsv
fact
mice
suscept
wildtyp
vsv
infect
dose
pfu
reduc
side
effect
intramuscular
rout
use
vsv
vaccin
sinc
mtdvsvbase
vaccin
significantli
attenu
chose
dose
pfu
vaccin
time
higher
wildtyp
vsv
lethal
dose
briefli
mice
immun
intramuscularli
safeti
antibodi
respons
monitor
found
complet
attenu
mice
exhibit
bodi
weight
loss
abnorm
reaction
fig
howev
lack
vsv
attenu
mutat
virul
mice
caus
death
day
morbid
day
requir
termin
other
mice
immun
lost
weight
recov
remain
healthi
shown
fig
mice
group
develop
high
level
antibodi
detect
elisa
fig
c
neutral
assay
fig
e
earli
week
postvaccin
ab
titer
remain
high
week
fig
e
addit
high
level
ab
detect
week
group
fig
g
week
postimmun
group
intraperiton
challeng
pfu
zikv
cambodian
strain
mice
control
unvaccin
challeng
group
immun
empti
pci
plasmid
develop
sever
clinic
sign
fig
sever
bodi
weight
loss
fig
sever
diseas
pci
control
group
mice
termin
day
contrast
mice
vaccin
either
exhibit
weight
loss
fig
zikv
associ
clinic
symptom
fig
zikv
viremia
measur
day
postchalleng
realtim
rtpcr
fig
b
averag
log
pfu
equival
zikv
detect
pci
control
group
day
low
zikv
pfu
equival
detect
day
group
none
group
day
high
level
zikv
detect
blood
pci
control
group
wherea
low
zikv
found
group
similarli
high
level
zikv
detect
brain
uteru
lung
spleen
pci
control
group
wherea
near
detect
limit
level
zikv
rna
found
organ
group
fig
addit
histolog
analysi
brain
tissu
show
complet
protect
mice
zikvinduc
enceph
fig
contrast
sever
enceph
character
neuron
necrosi
gliosi
neuron
satellitosi
neuronophagia
lymphocyt
perivascular
cuf
found
control
group
fig
brain
tissu
use
detect
vsv
rna
found
vsv
rna
detect
near
detect
limit
mice
vaccin
wherea
approxim
log
vsv
rna
detect
group
fig
suggest
significantli
attenu
data
demonstr
singl
low
dose
mtdvsvbase
vaccin
provid
complet
protect
zikv
challeng
mice
next
determin
whether
protein
alon
induc
protect
zikv
challeng
first
use
dna
vaccin
approach
know
dna
vaccin
safe
mice
gene
anchor
c
signal
peptid
clone
pci
vector
pciprm
express
intend
protein
e
transfect
cell
supplementari
fig
mice
vaccin
intramuscularli
pciprm
boost
plasmid
two
week
later
mice
pciprm
group
especif
elisa
neutral
ab
week
fig
high
level
zikv
especif
ab
week
fig
e
zikv
neutral
ab
detect
group
even
boost
fig
e
ab
detect
mice
week
fig
mice
vaccin
pciprm
protect
zikv
challeng
week
fig
b
interestingli
mice
group
weight
loss
quickli
recov
fig
mice
group
exhibit
clinic
sign
less
sever
pci
group
although
statist
differ
p
ttest
fig
overal
weight
loss
group
less
pci
control
group
fig
day
postchalleng
group
level
viremia
similar
pci
control
group
p
ttest
fig
day
group
significantli
less
viremia
p
ttest
fig
similarli
significantli
less
zikv
detect
spleen
uteru
lung
brain
group
compar
pci
control
group
p
p
ttest
fig
histolog
analysi
show
group
less
sever
enceph
compar
pci
group
fig
collect
data
demonstr
zikv
capabl
confer
partial
protect
zikv
challeng
mice
absenc
detect
zikv
neutral
ab
improv
protect
efficaci
recov
mtdvsv
express
alon
zikv
gene
anchor
c
insert
gene
junction
g
l
gene
supplementari
fig
western
blot
show
express
cell
significantli
higher
cell
fig
pilot
experi
show
still
caus
consider
weight
loss
mice
thu
decid
test
protect
efficaci
balbc
mice
briefli
balbc
mice
immun
intramuscularli
two
dose
intranas
one
dose
pfu
challeng
intraven
pfu
zikv
week
postimmun
found
trigger
significantli
higher
antibodi
mice
fig
posit
control
recombin
trigger
high
level
especif
antibodi
fig
day
postchalleng
mice
group
similar
level
viremia
p
ttest
significantli
lower
pci
control
p
ttest
fig
posit
control
viremia
level
group
near
detect
limit
fig
day
postchalleng
mice
group
detect
viremia
except
one
group
near
detect
limit
wherea
mice
pci
group
still
signific
level
viremia
p
ttest
fig
result
show
alon
capabl
trigger
signific
protect
zikvinduc
viremia
higher
protect
efficaci
final
valid
protect
efficaci
mice
monitor
bodi
weight
viremia
prolong
time
day
challeng
zikv
shown
fig
signific
differ
bodi
weight
gain
among
three
group
p
ttest
pfu
salin
normal
control
demonstr
high
safeti
profil
mice
expect
trigger
high
level
especif
fig
fig
antibodi
upon
challeng
zikv
cambodian
strain
mous
bodi
weight
viremia
monitor
everi
day
day
mice
receiv
salin
control
dead
day
postchalleng
fig
bodi
weight
group
indistinguish
normal
control
p
ttest
time
point
fig
salin
control
group
develop
high
level
zikv
induc
viremia
wherea
group
baselin
level
viremia
day
detect
viremia
day
fig
collect
high
safeti
efficaci
zikv
infect
recent
pandem
zikv
infect
alreadi
caus
signific
econom
health
emot
burden
highlight
urgent
need
develop
safe
highli
efficaci
zikv
vaccin
develop
mtdvsvbase
vaccin
platform
zikv
show
singl
dose
live
attenu
vsvbase
zikv
vaccin
express
prme
trigger
strong
zikvspecif
neutral
antibodi
cell
immun
respons
protect
balbc
mice
zikv
challeng
addit
show
first
time
protein
modul
zikvspecif
cell
immun
respons
alon
confer
partial
protect
zikvinduc
viremia
balbc
mice
lethal
zikv
challeng
mice
absenc
neutral
antibodi
respons
altogeth
result
demonstr
mtdvsvbase
zikv
vaccin
highli
promis
candid
zikv
highlight
play
import
role
regul
immun
respons
zikv
infect
vsv
excel
vaccin
extrem
high
level
gene
express
well
rapid
effici
vsvbase
vaccin
feasibl
initi
control
outbreak
highli
pathogen
agent
situat
high
risk
pathogen
would
outweigh
potenti
side
effect
vsv
vector
date
vsvbase
vaccin
candid
develop
filovirus
ebola
viru
marburg
viru
arenavirus
lassa
viru
lcmv
henipavirus
nipah
viru
hendra
viru
human
coronavirus
sar
mer
singl
dose
rvsvbase
vaccin
shown
highli
effect
small
anim
model
well
nonhuman
primat
administ
im
intraderm
oral
ad
rvsvbase
zikv
vaccin
candid
list
although
recent
report
rvsv
mutat
matrix
protein
express
prme
capabl
gener
matern
antibodi
protect
offspr
zikv
known
whether
immun
anim
directli
protect
zikv
challeng
studi
systemat
screen
immunogen
rvsv
express
varieti
zikv
antigen
includ
e
e
truncat
ae
ae
truncat
prme
prme
truncat
knowledg
first
time
util
coexpress
prme
potenti
antigen
vector
zikv
vaccin
candid
addit
use
viral
mtase
novel
approach
attenu
vsv
deliv
zikv
vaccin
demonstr
singl
immun
im
mtdvsvbase
vaccin
trigger
high
level
zikvspecif
ab
cell
immun
respons
provid
complet
protect
zikv
challeng
balbc
highli
sensit
mice
contrast
dna
vaccin
requir
high
dose
multipl
booster
vaccin
antibodi
undetect
balbc
mice
earli
time
point
fig
supplementari
tabl
result
suggest
efficaci
vsvbase
vaccin
much
higher
dna
vaccin
vsvbase
vaccin
offer
mani
advantag
includ
genet
stabil
express
multipl
antigen
low
cost
simplic
product
multipl
rout
administr
eas
manipul
ebola
viru
outbreak
africa
vsvbase
vaccin
rvsvebov
success
use
human
found
safe
addit
sever
vsvbase
vaccin
candid
oncolyt
agent
test
human
clinic
trial
like
analysi
safeti
efficaci
vsv
vector
human
forthcom
soon
facilit
use
vsvbase
vaccin
mass
vaccin
futur
found
zikv
alon
induc
partial
protect
zikv
challeng
balbc
mice
provid
substanti
protect
viremia
absenc
neutral
antibodi
overal
protect
efficaci
mtdvsvbase
vaccin
higher
dna
vaccin
approach
partial
protect
lethal
zikv
challeng
also
observ
mice
overal
diseas
sever
viremia
viru
burden
vaccin
group
significantli
lower
pci
control
group
mice
p
ttest
fig
flaviviru
nonstructur
glycoprotein
essenti
viral
replic
immun
evas
previous
shown
immun
purifi
recombin
passiv
administr
monoclon
antibodi
mab
protect
mice
lethal
infect
wnv
jev
denv
addit
vaccin
provid
substanti
cross
protect
heterolog
lethal
studi
highlight
valu
includ
protein
candid
vaccin
flavivirus
revis
manuscript
brault
et
al
report
intramuscular
immun
immunocompet
mice
modifi
vaccinia
ankara
mva
vector
express
vaccin
candid
provid
protect
lethal
intracerebr
dose
zikv
strain
howev
studi
evalu
efficaci
mice
highli
sensit
zikv
infect
find
confer
partial
protect
zikv
infect
highlight
altern
strategi
design
zikv
vaccin
current
effort
develop
zikv
subunit
vaccin
exclus
focus
prm
e
protein
reli
gener
high
level
neutral
ab
howev
report
antiflaviviru
ab
crossreact
speci
flaviviru
may
facilit
zikv
infect
antibodi
depend
enhanc
ade
sinc
absent
virion
ab
neutral
zikv
may
provid
altern
antigen
vaccin
develop
avoid
potenti
risk
diseas
also
found
play
import
role
modul
zikvspecif
immun
respons
express
e
protein
construct
rvsv
vector
delay
compar
prme
construct
probabl
due
differ
size
polyprotein
proteolyt
cleavag
polyprotein
importantli
induc
significantli
higher
cytokin
respons
p
ttest
suggest
coexpress
regul
zikvspecif
cell
immun
respons
critic
viru
anoth
advantag
trigger
high
level
antibodi
may
contribut
protect
perhap
fc
receptor
depend
mechan
fact
viremia
statist
lower
p
ttest
day
postchalleng
mice
fig
suggest
may
greater
protect
efficaci
either
higher
cell
immun
respons
ab
could
contribut
enhanc
protect
zikv
infect
one
major
concern
vsvbase
vaccin
safeti
particularli
sinc
vsv
neurotrop
studi
util
mtase
novel
approach
attenu
vsv
sinc
mrna
cap
methyl
diminish
viral
protein
translat
turn
would
diminish
viral
chose
rvsv
carri
singl
point
mutat
sam
bind
site
backbon
specif
defect
necessari
choos
mutat
mtase
activ
site
lack
methyl
enhanc
safeti
vsv
show
recombin
significantli
attenu
mice
wild
type
express
zikv
gene
particularli
dose
pfu
complet
attenu
mice
wherea
still
caus
mortal
addit
found
coexpress
prme
offer
addit
benefit
vsv
attenu
case
construct
significantli
attenu
prme
construct
mice
summari
develop
novel
mtdvsvbase
vaccin
coexpress
prm
e
protein
safe
highli
efficaci
mice
model
studi
also
highlight
major
gap
understand
role
protein
regul
zikv
immun
respons
protect
cell
atcc
vero
atcc
cell
atcc
purchas
american
type
cultur
collect
atcc
manassa
va
cell
kindli
provid
sean
whelan
stabli
express
rna
polymeras
clone
cell
cell
line
grown
dulbecco
modifi
eagl
medium
dmem
life
technolog
supplement
fb
zikv
cambodian
strain
provid
world
refer
center
emerg
virus
arbovirus
univers
texa
medic
branch
propag
vero
cell
titrat
use
standard
plaqu
plasmid
encod
vsv
n
pn
p
pp
l
pl
gene
infecti
cdna
clone
viral
genom
gener
gift
gail
plasmid
gxxl
contain
smai
xhoi
g
l
gene
junction
kindli
provid
sean
whelan
fulllength
envelop
e
gene
amino
acid
e
truncat
mutant
amino
acid
amino
acid
amino
acid
lack
predict
stemtransmembran
domain
tm
amplifi
infecti
cdna
clone
zikv
cambodian
strain
genbank
access
high
fidel
pcr
dna
fragment
digest
smai
xhoi
clone
pvsv
gxxl
site
result
plasmid
design
pvsv
e
pvsv
pvsv
pvsv
use
strategi
anchor
c
signal
peptid
e
clone
pvsv
gxxl
smai
xhoi
site
result
construct
pvsv
ae
pvsv
pvsv
pvsv
respect
addit
anchor
cpremembraneenvelop
prme
anchor
cprme
truncat
mutant
anchor
cpremembraneenvelopenonstructur
protein
gene
clone
pvsv
gxxl
smai
xhoi
site
result
plasmid
design
pvsv
prme
pvsv
pvsv
pvsv
pvsv
similarli
anchor
gene
amino
acid
clone
pvsv
gxxl
smai
xhoi
site
result
plasmid
name
pvsv
attenu
vsv
vector
took
advantag
point
mutat
larg
l
polymeras
protein
render
recombin
viru
specif
defect
mrna
cap
methyl
use
sitedirect
mutagenesi
mutat
introduc
pvsv
e
pvsv
ae
pvsv
prme
pvsv
pvsv
result
construct
pvsv
pvsv
pvsv
pvsv
pvsv
respect
prepar
dna
vaccin
plasmid
anchor
cprme
anchor
gene
clone
pci
vector
promega
result
construct
pciprm
respect
construct
confirm
sequenc
recoveri
recombin
vsv
rvsv
infecti
clone
carri
describ
briefli
rvsv
recov
cotransfect
plasmid
encod
vsv
genom
support
plasmid
encod
vsv
nucleocapsid
complex
pn
pp
pl
cell
infect
recombin
vaccinia
viru
express
rna
polymeras
kindli
provid
dr
bernard
moss
h
posttransfect
cell
cultur
fluid
collect
filter
filter
recombin
viru
amplifi
cell
subsequ
virus
plaqu
purifi
describ
individu
plaqu
isol
seed
stock
amplifi
cell
viral
titer
determin
plaqu
assay
perform
vero
cell
viral
rna
extract
recombin
vsv
use
rneasi
minikit
qiagen
valencia
ca
accord
manufactur
instruct
zikv
gene
amplifi
one
step
rtpcr
kit
qiagen
use
primer
anneal
vsv
g
gene
posit
l
gene
posit
number
refer
complet
vsv
indiana
genom
sequenc
amplifi
product
analyz
agaros
gel
electrophoresi
sequenc
confluent
cell
infect
individu
virus
multipl
infect
moi
h
absorpt
inoculum
remov
cell
wash
twice
dulbecco
modifi
eagl
medium
dmem
fresh
dmem
supplement
fetal
bovin
serum
ad
infect
cell
incub
aliquot
cell
cultur
fluid
remov
indic
interv
viru
titer
determin
plaqu
assay
vero
cell
confluent
cell
infect
rvsv
express
zikv
antigen
parent
rvsv
moi
describ
h
postinfect
cell
wash
methionin
cysteinefre
c
medium
incub
fresh
c
medium
supplement
actinomycin
h
incub
medium
replac
c
medium
supplement
easytag
perkinelm
wellesley
h
incub
cytoplasm
extract
prepar
analyz
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
describ
label
protein
detect
use
phosphorimag
origin
uncrop
imag
sdspage
shown
supplementari
figur
cell
infect
rvsv
express
zikv
antigen
describ
dna
vaccin
plasmid
cell
transfect
pci
pciprm
use
lipofectimin
indic
time
postinfect
cell
cultur
medium
harvest
clarifi
g
min
concentr
g
h
meantim
cell
lyse
lysi
buffer
contain
sd
protein
separ
sdspage
transfer
hybond
enhanc
chemiluminesc
nitrocellulos
membran
amersham
mini
transblot
electrophoret
transfer
cell
biorad
blot
probe
rabbit
antizikv
e
cat
alpha
diagnost
intl
inc
san
antonio
tx
antibodi
cat
alpha
diagnost
intl
inc
dilut
follow
horseradish
peroxidaseconjug
goat
antirabbit
igg
secondari
antibodi
cat
santa
cruz
dilut
blot
develop
supersign
west
pico
chemiluminesc
substrat
thermo
scientif
expos
kodak
biomax
mr
film
origin
uncrop
imag
western
blot
shown
supplementari
fig
recombin
rvsve
rvsvprme
inocul
confluent
flask
cell
moi
volum
ml
dmem
h
postabsorpt
ml
dmem
supplement
fetal
bovin
serum
ad
cultur
infect
cell
incub
h
cell
cultur
fluid
harvest
extens
cytopath
effect
cpe
observ
cell
cultur
fluid
clarifi
centrifug
min
viru
concentr
wtvol
sucros
cushion
centrifug
h
ty
rotor
beckman
pellet
resuspend
nte
buffer
mm
nacl
mm
tri
mm
edta
ph
purifi
cscl
isopycn
gradient
centrifug
h
rotor
beckman
final
pellet
resuspend
ml
nte
buffer
purifi
zikv
vlp
analyz
sdspage
western
blot
electron
microscopi
protein
concentr
vlp
measur
use
bradford
reagent
sigma
chemic
co
st
loui
mo
ten
confluent
flask
vero
cell
infect
zikv
cambodian
strain
moi
volum
ml
dmem
h
absorpt
ml
dmem
supplement
fetal
bovin
serum
ad
infect
cell
incub
h
extens
cytopath
effect
cpe
observ
cell
cultur
fluid
harvest
zikv
purif
procedur
vlp
purif
mention
negativestain
electron
microscopi
purifi
vlp
zikv
perform
describ
previous
briefli
vlp
zikv
suspens
fix
copper
grid
electron
microscopi
scienc
inc
neg
stain
ammonium
molybd
viru
particl
visual
use
fei
tecnai
spirit
transmiss
electron
microscop
tem
kv
microscopi
imag
facil
ohio
state
univers
imag
captur
megaview
iii
sidemount
chargecoupleddevic
camera
soft
imag
system
lakewood
co
figur
process
use
adob
photoshop
softwar
adob
system
san
jose
ca
mice
hous
within
ular
facil
ohio
state
univers
approv
institut
laboratori
anim
care
use
committe
iacuc
guidelin
protocol
inocul
group
separ
hous
rodent
cage
biosafeti
level
condit
experi
determin
whether
vsv
construct
immunogen
balbc
mice
sixti
specificpathogenfre
femal
balbc
mice
charl
river
laboratori
wilmington
randomli
divid
group
mice
per
group
mice
group
inocul
parent
rvsv
insert
mice
group
inocul
nine
differ
rvsv
express
zikv
antigen
rvsve
rvsvprme
mice
group
inocul
dmem
serv
uninfect
control
normal
control
mice
group
immun
dna
vaccin
pciprm
vsv
mous
inocul
intranas
dose
pfu
volum
dna
vaccin
mice
immun
intramuscularli
pciprm
boost
dose
two
week
later
inocul
anim
evalu
twice
everi
day
mortal
presenc
symptom
vsv
infect
sever
clinic
sign
associ
vsv
infect
score
base
follow
criteria
grade
sever
character
ruffl
fur
hyperexcit
tremor
circl
paralysi
grade
moder
character
ruffl
fur
neurolog
symptom
circl
grade
mild
character
ruffl
fur
neurolog
symptom
grade
defin
symptom
bodi
weight
mous
monitor
everi
three
day
blood
sampl
collect
mous
weekli
bleed
facial
vein
serum
isol
antibodi
detect
week
postinocul
mice
euthan
experi
determin
antibodi
cell
immun
respons
trigger
mtdvsv
balbc
mice
thirti
spf
femal
balbc
mice
charl
river
laboratori
randomli
divid
six
group
mice
per
group
mice
group
inocul
dmem
serv
unimmun
control
normal
control
mice
group
immun
rvsv
mice
immun
intranas
dose
pfu
per
mous
immun
anim
evalu
daili
bodi
weight
mortal
presenc
symptom
vsv
infect
blood
sampl
collect
mous
weekli
bleed
facial
vein
serum
isol
antibodi
detect
week
postinocul
mice
euthan
whole
blood
spleen
isol
mous
cell
assay
experi
determin
whether
mtdvsv
vaccin
protect
balbc
mice
viremia
day
zikv
challeng
seventi
spf
balbc
mice
charl
river
laboratori
randomli
divid
group
per
group
femal
male
mice
group
immun
dmem
mice
group
immun
dna
vaccin
mice
group
serv
normal
control
immun
dmem
unchalleng
vsv
mice
inocul
intranas
dose
pfu
per
mous
dna
vaccin
mice
immun
intramuscularli
pciprm
boost
dose
week
later
immun
presenc
vsv
symptom
induc
mtdvsvbase
zikv
vaccin
candid
evalu
twice
day
week
postimmun
mice
group
challeng
intraven
zikv
cambodian
strain
dose
pfu
per
mous
h
prior
zikv
challeng
mice
intraperiton
administ
mg
leinco
technolog
fenton
mo
block
antibodi
challeng
anim
evalu
twice
daili
mortal
presenc
symptom
zikv
infect
bodi
weight
mous
monitor
daili
day
postchalleng
mice
group
euthan
blood
brain
lung
liver
spleen
mous
collect
viru
quantif
histolog
evalu
experi
determin
whether
mtdvsv
vaccin
protect
balbc
mice
viremia
day
postchalleng
mice
group
immun
salin
mice
group
serv
normal
control
unimmun
unchalleng
experiment
procedur
ident
experi
except
mice
euthan
day
challeng
zikv
cambodian
strain
experi
determin
whether
mtdvsv
vaccin
dna
vaccin
protect
mice
zikv
challeng
thirti
five
femal
mice
jackson
laboratori
randomli
divid
group
per
group
mice
group
immun
intramuscularli
pci
pciprm
dose
dna
per
mous
two
week
later
mice
group
boost
intramuscularli
plasmid
dose
mice
group
administ
intramuscularli
use
singl
dose
pfu
per
mous
mice
group
serv
unvaccin
unchalleng
control
immun
mice
evalu
everi
three
day
bodi
weight
safeti
mtdvsvbase
zikv
vaccin
candid
evalu
twice
day
blood
sampl
collect
week
mous
detect
antibodi
week
postimmun
mice
group
intraperiton
challeng
zikv
cambodian
strain
dose
pfu
per
mous
challeng
anim
evalu
twice
everi
day
mortal
presenc
symptom
zikv
infect
sever
clinic
diseas
score
base
follow
criteria
heathi
mild
moder
sever
earli
remov
requir
bodi
weight
mous
monitor
daili
blood
collect
day
detect
viremia
day
postchalleng
mice
group
euthan
brain
lung
uterusovari
spleen
mous
collect
viru
quantif
histolog
evalu
experi
determin
whether
alon
protect
balbc
mice
viremia
twenti
five
femal
balbc
mice
randomli
divid
group
per
group
mice
group
immun
dmem
pci
vsv
mice
inocul
intranas
dose
pfu
per
mous
dna
vaccin
mice
immun
intramuscularli
plasmid
boost
dose
two
week
later
week
postimmun
mice
group
intraven
challeng
zikv
cambodian
strain
dose
pfu
per
mous
h
prior
zikv
challeng
mice
intraperiton
administ
mg
leinco
technolog
block
antibodi
day
postchalleng
blood
collect
mous
detect
viremia
realtim
rtpcr
experi
valid
safeti
immunogen
mice
three
group
studi
mice
group
immun
intramuscularli
singl
dose
pfu
per
mous
mice
group
serv
unimmun
challeng
control
normal
control
unimmun
unchalleng
blood
collect
mous
weekli
antibodi
detect
week
mice
group
intraperiton
challeng
zikv
cambodian
strain
dose
pfu
per
mous
challeng
mice
monitor
bodi
weight
chang
viremia
everi
day
day
ninetysixwel
plate
first
coat
highli
purifi
zikv
e
protein
mybiosourc
inc
san
diego
ca
mm
buffer
ph
per
well
overnight
block
bovin
serum
albumin
bsa
wv
pb
h
subsequ
individu
serum
sampl
test
zikvspecif
ab
antigenco
plate
briefli
serum
sampl
serial
dilut
ad
e
proteinco
well
incub
room
temperatur
h
plate
wash
five
time
phosphatebuff
salin
pb
tween
follow
incub
goat
antimous
igg
horseradish
peroxidas
hrp
conjug
secondari
ab
sigma
dilut
h
plate
wash
develop
tmb
stop
moll
optic
densiti
od
nm
determin
biotek
micropl
reader
endpoint
titer
determin
reciproc
highest
dilut
absorb
valu
greater
background
level
dmem
control
ab
titer
calcul
geometr
mean
titer
gmt
zikvspecif
neutral
ab
determin
use
microneutr
mn
assay
describ
briefli
serum
sampl
serial
dilut
twofold
micropl
viru
solut
contain
pfu
zikvcambodian
strain
ad
serum
dilut
incub
h
mixtur
transfer
plate
contain
confluent
vero
cell
monolay
incub
h
cell
fix
volvol
phosphatebuff
paraformaldehyd
h
wash
three
time
pb
permeat
volvol
tritonx
room
temperatur
min
wash
three
time
zikv
e
monoclon
antibodi
mybiosourc
inc
ad
well
dilut
incub
h
follow
wash
pb
three
time
horseradish
peroxidaseconjug
goat
antirabbit
igg
secondari
antibodi
santa
cruz
dilut
ad
well
incub
h
follow
wash
pb
three
time
plate
develop
aec
substrat
h
room
temperatur
stain
plaqu
well
count
light
microscop
half
maxim
inhibitori
concentr
neutral
antibodi
mice
serum
calcul
base
number
plaqu
well
compar
averag
valu
dmem
group
determin
natur
cell
respons
support
develop
zikvspecif
ab
respons
rvsv
express
zikv
antigen
analyz
cytokin
product
zikv
especif
spleen
cell
specif
spleen
cell
asept
remov
mice
day
immun
minc
press
cell
strainer
red
blood
cell
remov
incub
ammonium
chlorid
follow
seri
wash
rpmi
cell
resuspend
rpmi
supplement
mm
lglutamin
mm
sodium
pyruv
mm
hepe
uml
penicillin
streptomycin
fetal
calf
serum
cell
concentr
adjust
cellsml
ad
well
well
per
spleen
sampl
microtit
plate
cultur
either
alon
presenc
zikv
e
protein
day
atmospher
cultur
supernat
collect
well
frozen
analysi
secret
cytokin
use
bioplex
pro
mous
cytokin
standard
group
biorad
laboratori
inc
hercul
ca
per
manufactur
instruct
frequenc
zikvspecif
cell
tfh
cell
determin
intracellular
stain
correspond
anticytokin
ab
dilut
addit
incub
presenc
pma
ionomycin
cytokinespecif
antibodi
includ
alexa
fluor
cat
alexa
fluor
cat
alexa
fluor
anti
cat
percp
cat
pe
cat
alexa
fluor
cat
cat
brilliant
violet
cat
brilliant
violet
cat
purchas
biolegend
san
diego
ca
cell
analyz
aid
attun
flow
cytomet
data
express
mean
posit
cell
standard
deviat
indic
time
point
zikv
challeng
blood
collect
organ
recov
organ
weigh
homogen
use
beadbeat
apparatu
magna
lyser
roch
total
rna
extract
tissu
sampl
blood
use
trizol
reagent
life
technolog
carlsbad
ca
revers
transcript
rt
conduct
use
primer
target
capsid
c
gene
zikv
superscript
iii
transcriptas
kit
invitrogen
carlsbad
ca
rt
product
use
perform
realtim
pcr
use
primer
specif
target
e
gene
zikv
forward
revers
stepon
realtim
pcr
system
appli
biosystem
standard
curv
gener
use
serial
dilut
zikv
rna
extract
known
pfu
titer
infecti
viru
amplif
cycl
use
min
min
cycl
min
threshold
detect
fluoresc
background
set
within
exponenti
phase
amplif
curv
assay
dilut
standard
viral
rna
gener
negativecontrol
sampl
doubledistil
water
includ
assay
viral
burden
express
scale
viral
rna
equival
per
gram
per
millilit
similarli
total
rna
brain
tissu
use
quantif
vsv
rna
use
primer
anneal
vsv
l
gene
shown
rna
copi
per
gram
use
plasmid
encod
vsv
genom
standard
curv
half
tissu
brain
lung
uterusovari
spleen
experi
preserv
volvol
phosphatebuff
paraformaldehyd
fix
tissu
embed
paraffin
section
stain
hematoxylineosin
examin
histolog
chang
light
microscopi
pathologist
blind
group
quantit
analysi
perform
either
densitometr
scan
autoradiograph
use
phosphorimag
typhoon
ge
healthcar
imagequ
tl
softwar
ge
healthcar
piscataway
nj
experi
three
replic
anim
sampl
exclud
analysi
data
collect
assess
blindli
group
alloc
experi
statist
analysi
perform
oneway
multipl
comparison
use
spss
statist
analysi
softwar
spss
inc
chicago
il
p
valu
consid
statist
signific
materi
reagent
data
report
manuscript
avail
author
upon
request
author
declar
data
support
find
studi
avail
articl
supplementari
inform
file
avail
correspond
author
upon
request
